p.97 抽出テキスト

568. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021;397: 2476–86. https://doi.org/10.1016/s0140-6736(21)00788-1 569. Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the global SYMPLICITY registry. Eur Heart J 2019;40:3474–82. https://doi.org/ 10.1093/eurheartj/ehz118 570. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 trial. Lancet 2022;400:1405–16. https://doi.org/10.1016/s0140-6736(22)01787-1 571. Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022; 399:1401–10. https://doi.org/10.1016/s0140-6736(22)00455-x 572. Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, et al. Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention 2022;18: e677–85. https://doi.org/10.4244/eij-d-22-00305 573. Al Ghorani H, Kulenthiran S, Recktenwald MJM, Lauder L, Kunz M, Götzinger F, et al. 10-year outcomes of catheter-based renal denervation in patients with resistant hypertension. J Am Coll Cardiol 2023;81:517–9. https://doi.org/10.1016/j.jacc.2022.11.038 574. Stone P, Campbell J, Thompson S, Walker J. A prospective, randomized study comparing ultrasound versus fluoroscopic guided femoral arterial access in noncardiac vascular patients. J Vasc Surg 2020;72:259–67. https://doi.org/10.1016/j.jvs.2019.09.051 575. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;377: 1409–20. https://doi.org/10.1016/s0140-6736(11)60404-2 576. Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP, et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention 2020;16:89–96. https://doi.org/ 10.4244/eij-d-19-00902 577. Sanders MF, Reitsma JB, Morpey M, Gremmels H, Bots ML, Pisano A, et al. Renal safety of catheter-based renal denervation: systematic review and meta-analysis. Nephrol Dial Transplant 2017;32:1440–7. https://doi.org/10.1093/ndt/gfx088 578. Ahmad Y, Francis DP, Bhatt DL, Howard JP. Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials. JACC Cardiovasc Interv 2021;14:2614–24. https://doi.org/10.1016/j.jcin.2021.09.020 579. Chowdhury EK, Reid CM, Zomer E, Kelly DJ, Liew D. Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: a best case scenario. Am J Hypertens 2018;31:1156–63. https://doi.org/10.1093/ajh/hpy108 580. Sharp ASP, Cao KN, Esler MD, Kandzari DE, Lobo MD, Schmieder RE, et al. Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. Eur Heart J Qual Care Clin Outcomes 2024:qcae001. https://doi.org/10.1093/ ehjqcco/qcae001 581. Fengler K, Reimann P, Rommel KP, Kresoja K-P, Blazek S, Unterhuber M, et al. Comparison of long-term outcomes for responders versus non-responders following renal denervation in resistant hypertension. J Am Heart Assoc 2021;10:e022429. https:// doi.org/10.1161/jaha.121.022429 582. Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M, et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol 2022;80:1871–80. https://doi.org/10. 1016/j.jacc.2022.08.802 583. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. ESC guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191 584. Singh RR, Denton KM. Renal denervation. Hypertension 2018;72:528–36. https://doi. org/10.1161/hypertensionaha.118.10265 585. Barbato E, Azizi M, Schmieder RE, Lauder L, Böhm M, Brouwers S, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2023;44:1313–30. https://doi.org/ 10.1093/eurheartj/ehad054 586. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370: 1393–401. https://doi.org/10.1056/NEJMoa1402670 587. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015;65:1202–8. https://doi.org/10.1161/hypertensionaha.115.05283 588. Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24–h blood pressure-based trial. J Hypertens 2016;34:1639–47. https://doi.org/10.1097/hjh.0000000000000977 589. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017;390:2160–70. https://doi.org/ 10.1016/s0140-6736(17)32281-x 590. Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res 2022;45:221–31. https://doi. org/10.1038/s41440-021-00754-7 591. Neuzil P, Merkely B, Erglis A, Marinskis G, de Groot JR, Schmidinger H, et al. Pacemaker-mediated programmable hypertension control therapy. J Am Heart Assoc 2017;6:e006974. https://doi.org/10.1161/jaha.117.006974 592. Kalarus Z, Merkely B, Neužil P, Grabowski M, Mitkowski P, Marinskis G, et al. Pacemaker-based cardiac neuromodulation therapy in patients with hypertension: a pilot study. J Am Heart Assoc 2021;10:e020492. https://doi.org/10.1161/jaha.120. 020492 593. Musini VM, Tejani AM, Bassett K, Puil L, Wright JM. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev 2019;6:CD000028. https://doi. org/10.1002/14651858.CD000028.pub3 594. Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev 2017;8:CD008276. https://doi.org/10.1002/14651858.CD008276.pub2 595. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens 2016;34: 1921–32. https://doi.org/10.1097/hjh.0000000000001052 596. Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res 2019;124:1045–60. https://doi.org/10.1161/circresaha.118.313236 597. Frey L, Gravestock I, Pichierri G, Steurer J, Burgstaller JM. Serious adverse events in patients with target-oriented blood pressure management: a systematic review. J Hypertens 2019;37:2135–44. https://doi.org/10.1097/hjh.0000000000002176 598. Palmer SC, Sciancalepore M, Strippoli GF. Trial quality in nephrology: how are we measuring up? Am J Kidney Dis 2011;58:335–7. https://doi.org/10.1053/j.ajkd.2011. 06.006 599. Carriazo S, Sarafidis P, Ferro CJ, Ortiz A. Blood pressure targets in CKD 2021: the never-ending guidelines debacle. Clin Kidney J 2022;15:845–51. https://doi.org/10. 1093/ckj/sfac014 600. Kessler A, Sollie S, Challacombe B, Briggs K, Van Hemelrijck M. The global prevalence of erectile dysfunction: a review. BJU Int 2019;124:587–99. https://doi.org/10. 1111/bju.14813 601. Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich) 2006;8:359–64. https://doi. org/10.1111/j.1524-6175.2005.05285.x 602. Ismail SB, Noor NM, Hussain NHN, Sulaiman Z, Shamsudin MA, Irfan M. Angiotensin receptor blockers for erectile dysfunction in hypertensive men: a brief meta-analysis of randomized control trials. Am J Mens Health 2019;13:1557988319892735. https://doi. org/10.1177/1557988319892735 603. Lawson AJ, Hameed MA, Brown R, Cappuccio FP, George S, Hinton T, et al. Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J Hypertens 2020;38:1165–73. https:// doi.org/10.1097/hjh.0000000000002398 604. Choudhry NK, Kronish IM, Vongpatanasin W, Ferdinand KC, Pavlik VN, Egan BM, et al. Medication adherence and blood pressure control: a scientific statement from the American heart association. Hypertension 2022;79:e1–14. https://doi.org/10.1161/ hyp.0000000000000203 605. Liao CT, Toh HS, Sun L, Yang C-T, Hu A, Wei D, et al. Cost-effectiveness of intensive vs standard blood pressure control among older patients with hypertension. JAMA Netw Open 2023;6:e230708. https://doi.org/10.1001/jamanetworkopen.2023.0708 606. O’Donoghue P, O’Halloran AM, Kenny RA, Romero-Ortuno R. Do the frail experience more adverse events from intensive blood pressure control? A 2-year prospective study in the Irish Longitudinal Study on Ageing (TILDA). EClinicalMedicine 2022;45: 101304. https://doi.org/10.1016/j.eclinm.2022.101304 607. Sexton DJ, Canney M, O’Connell MDL, Moore P, Little MA, O’Seaghdha CM, et al. Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT. JAMA Intern Med 2017;177:1385–7. https://doi.org/10.1001/ jamainternmed.2017.2924 608. Masoli JAH, Sheppard JP, Rajkumar C. Hypertension management in older patients-are the guideline blood pressure targets appropriate? Age Ageing 2022;51:afab226. https:// doi.org/10.1093/ageing/afab226 609. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026